Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development

Cancer Research

Volumn 68, Issue 5, 2008, Pages 1329-1337

  Van Veelen, Wendy ^a,e   Van Gasteren, Carola J R ^a   Acton, Dennis S ^a,c   Franklin, David S ^b,d   Berger, Ruud ^a   Lips, Cornelis J M ^a   Höppener, Jo W M ^a,f  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b PURDUE UNIVERSITY   (United States)

^c MucoVax BV   (Netherlands)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE INACTIVATION; GENE LOSS; GENE MUTATION; GENETIC ASSOCIATION; INCIDENCE; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE RET; P18 GENE; P27 GENE; PRIORITY JOURNAL; PROTO ONCOGENE; RET2B ONCOGENE; SOMATIC MUTATION; THYROID MEDULLARY CARCINOMA; TRANSGENIC MOUSE;

ANIMALS; CALCITONIN; CARCINOMA, MEDULLARY; CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P18; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS;

EID: 40449141526     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5754     Document Type: Article

References (34)

1. Sizemore GW, Health H III, Carney JA. Multiple endocrine neoplasia type 2. Clin Endocrinol Metab 1980;9:299-315.
2. Eng C, Mulligan LM. Mutations of the RET protooncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease. Hum Mutat 1997;9:97-109.
3. Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 1995;15:1613-9.
4. Santoro M, Carlomagno F, Romano A, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995;267:381-3.
5. Machens A, Gimm O, Hinze R, Hoppner W, Boehm BO, Dralle H. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab 2001;86:1104-9.
6. Mulligan LM, Marsh DJ, Robinson BG, et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 1995;238:343-6.
7. Acton DS, Velthuyzen D, Lips CJ, Hoppener JW. Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice. Oncogene 2000;19:3121-5.
8. Marsh DJ, Theodosopoulos G, Martin-Schulte K, et al. Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1866-72.
9. Mathew CG, Smith BA, Thorpe K, et al. Deletion of genes on chromosome 1 in endocrine neoplasia. Nature 1987;328:524-6.
10. Yang KP, Nguyen CV, Castillo SG, Samaan NA. Deletion mapping on the distal third region of chromosome 1p in multiple endocrine neoplasia type IIA. Anticancer Res 1990;10:527-33.
11. Franklin DS, Godfrey VL, O'Brien DA, Deng C, Xiong Y. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol 2000;20:6147-58.
12. 1 cyclin-dependent kinases. Genes Dev 1995;9:1149-63.
13. 1-phase progression. Genes Dev 1999;13:1501-12.
14. Park MS, Rosai J, Nguyen HT, Capodieci P, Cordon-Cardo C, Koff A. p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc Natl Acad Sci U S A 1999;96:6382-7.
15. Takahashi C, Contreras B, Bronson RT, Loda M, Ewen ME. Genetic interaction between Rb and K-ras in the control of differentiation and tumor suppression. Mol Cell Biol 2004;24:10406-15.
16. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet 1994;7:480-4.
17. Coxon AB, Ward JM, Geradts J, Otterson GA, Zajac-Kaye M, Kaye FJ. RET cooperates with RB/p53 inactivation in a somatic multi-step model for murine thyroid cancer. Oncogene 1998;17:1625-8.
18. Franklin DS, Godfrey VL, Lee H, et al. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 1998;12:2899-911.
19. Lips CJ, Hoppener JW, Thijssen JH. Medullary thyroid carcinoma: role of genetic testing and calcitonin measurement. Ann Clin Biochem 2001;38:168-79.
20. Bai F, Pei XH, Godfrey VL, Xiong Y. Haploinsufficiency of p18(INK4c) sensitizes mice to carcinogen-induced tumorigenesis. Mol Cell Biol 2003;23:1269-77.
21. Cohen R, Campos JM, Salaun C, et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC). J Clin Endocrinol Metab 2000;85:919-22.
22. Polyak K. The p27Kip1 tumor suppressor gene: still a suspect or proven guilty? Cancer Cell 2006;10:352-4.
23. Bai F, Pei XH, Nishikawa T, Smith MD, Xiong Y. p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors. Mol Cell Biol 2007;27:1495-504.
24. Roussel MF. The INK4 family of cell cycle inhibitors in cancer. Oncogene 1999;18:5311-7.
25. Zindy F, Quelle DE, Roussel MF, Sherr CJ. Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 1997;15:203-11.
26. Karnik SK, Hughes CM, Gu X, et al. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci U S A 2005;102:14659-64.
27. Milne TA, Hughes CM, Lloyd R, et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A 2005;102:749-54.
28. Joshi PP, Kulkarni MV, Yu BK, et al. Simultaneous down-regulation of CDK inhibitors p18(Ink4c) and p27(Kip1) is required for MEN2A-RET-mediated mitogenesis. Oncogene 2007;26:554-70.
29. Myers TK, Andreuzza SE, Franklin DS. p18INK4c and p27KIP1 are required for cell cycle arrest of differentiated myotubes. Exp Cell Res 2004;300:365-78.
30. Swarbrick A, Lee CS, Sutherland RL, Musgrove EA. Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells. Mol Cell Biol 2000;20:2581-91.
31. Delaval B, Birnbaum D. A cell cycle hypothesis of cooperative oncogenesis [review]. Int J Oncol 2007;30:1051-8.
32. Harvey M, Vogel H, Lee EY, Bradley A, Donehower LA. Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Res 1995;55:1146-51.
33. Damo LA, Snyder PW, Franklin DS. Tumorigenesis in p27/p53- and p18/p53-double null mice: functional collaboration between the pRb and p53 pathways. Mol Carcinog 2005;42:109-20.
34. Uziel T, Zindy F, Xie S, et al. The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev 2005;19:2656-67.